India’s Leading Maternity and Birthing Care Hospital Group, Cloudnine, Adopts Masimo SET® Technology to Screen Infants for CCHD
Masimo (NASDAQ: MASI) announced today that Cloudnine Hospital Group – a leader in providing premier quality healthcare to women and children in India – has upgraded system-wide to Masimo SET® pulse oximetry.
This Smart News Release features multimedia. View the full release here: http://www.businesswire.com/news/home/20151116005666/en/
Congenital heart disease (CHD) is the most common birth defect and it is estimated that nearly one out of every 100 babies is born with CHD. It has been reported that around 78,000 infants die because of congenital heart disease in India every year.1 Critical congenital heart disease (CCHD), defined as CHD causing death or requiring invasive intervention in the neonatal period, occurs in one to two newborns per 1,000 live births.2
“We evaluated several monitors before selecting Masimo’s superior SET® technology for all 16 Cloudnine Hospitals,” said Dr. Kishore Kumar, Chairman and Senior Neonatologist, Cloudnine Hospitals. “Masimo SET® will enhance our existing protocols to provide superior screening and ensure that every baby born here now has the opportunity to live a healthy life. Our hope is that universal CCHD screening become mandatory for every child born in India.”
“Early detection is key in this fragile patient population,” said Joe Kiani, Founder and CEO of Masimo. “It’s exciting to see the adoption of CCHD screening in India. Cloudnine’s hospitals have the best in class morbidity and mortality outcomes in the country – 0% maternal mortality and a 99.83% survival rate for babies. When we developed SET® , we didn’t realize how many wonderful new applications our Measure-Through Motion and Low Perfusion™ technology would make possible – so it’s especially gratifying that we can help clinicians around the world save the lives of so many babies.”
In a study of newborns, researchers have found CCHD was detected 63% of the time by standard screening and 83% of the time when screening with Masimo SET® was added.3 Over 100 million patients are monitored with Masimo SET® pulse oximeters around the world and in more than 100 comparative studies Masimo SET® outperformed other technologies.4,5 Researchers have found that Masimo SET® in combination with changes in clinical practice led to an increase of 31% in the detection of newborns with CCHD when used as a part of the CCHD screening protocol.3
Cloudnine hospitals are also the first in the country to make a formal patient safety commitment to the World Patient Safety Movement Foundation. This non-profit organization is dedicated to eradicating preventable patient deaths in hospitals around the world. With this step, Cloudnine joins an elite group of over 1200 hospitals worldwide that have made public commitments to implementing Actionable Patient Safety Solutions in their respective organizations.
For more information on Masimo products, go to www.masimo.com .
For more information on the World Patient Safety Movement Foundation, go to www.patientsafetymovement.org .
@MasimoInnovates | #Masimo
2 Zhao QM, Ma XJ, Ge XL, Liu F, Yan WL, Wu L, Ye M, Liang XC, Zhang J, Gao Y, Jia B, Huang GY; Neonatal Congenital Heart Disease screening group. Pulse oximetry with clinical assessment to screen for congenital heart disease in neonates in China: a prospective study. Lancet. 2014 Aug 30;384(9945):747-54.
3 de-Wahl Granelli A, Wennergren M, Sandberg K, Mellander M, Bejlum C, Inganäs L, Eriksson M, Segerdahl N, Agren A, Ekman-Joelsson BM, Sunnegårdh J, Verdicchio M, Ostman-Smith I. Impact of pulse oximetry screening on the detection of duct dependent congenital heart disease: a Swedish prospective screening study in 39,821 newborns. BMJ. 2009 Jan 8;338:a3037.
4 Data on file.
5 All studies available at http://www.masimo.com/cpub/clinical-evidence.htm .
Set up in 2007 by the renowned neonatologist Dr. R. Kishore Kumar, in partnership with investing partners Matrix Partners and Sequoia Capital, Cloudnine is India’s premier destination for comprehensive maternal, gynecological, neonatal, and pediatric care. The organization’s vision is to effectively bridge the gap between Indian and international standards through a combination of clinical excellence, comprehensive care and an atmosphere of well-being, to ensure world-class standards in woman and child healthcare.
Masimo (NASDAQ: MASI) is the global leader in innovative noninvasive monitoring technologies. Our mission is to improve patient outcomes and reduce the cost of care by taking noninvasive monitoring to new sites and applications. In 1995, the company debuted Masimo SET® Measure-through-Motion and Low Perfusion™ pulse oximetry, which has been shown in multiple studies to significantly reduce false alarms and accurately monitor for true alarms. The benefits of Masimo SET® have been proven in more than 100 independent and objective studies and it is estimated to be used on more than 100 million patients in leading hospitals and other healthcare settings around the world. In 2005, Masimo introduced rainbow® Pulse CO-Oximetry technology, allowing noninvasive and continuous monitoring of blood constituents that previously could only be measured invasively, including total hemoglobin (SpHb®), oxygen content (SpOC™), carboxyhemoglobin (SpCO®), methemoglobin (SpMet®), and Pleth Variability Index (PVI®), in addition to SpO2, pulse rate, and perfusion index (PI). Additional information about Masimo and its products may be found at www.masimo.com .
This press release includes forward-looking statements as defined in Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, in connection with the Private Securities Litigation Reform Act of 1995. These forward-looking statements are based on current expectations about future events affecting us and are subject to risks and uncertainties, all of which are difficult to predict and many of which are beyond our control and could cause our actual results to differ materially and adversely from those expressed in our forward-looking statements as a result of various risk factors, including, but not limited to: risks related to our assumptions regarding the repeatability of clinical results; risks related to our belief that Masimo's unique noninvasive measurement technologies, including: total hemoglobin (SpHb®) contribute to positive clinical outcomes and patient safety; risks related to our belief that Masimo noninvasive medical breakthroughs provide cost-effective solutions with comparable accuracy and unique advantages, including: immediate and continuous results that enable earlier treatment without causing invasive trauma in all patients and in every clinical situation; as well as other factors discussed in the "Risk Factors" section of our most recent reports filed with the Securities and Exchange Commission ("SEC "), which may be obtained for free at the SEC's website at www.sec.gov . Although we believe that the expectations reflected in our forward-looking statements are reasonable, we do not know whether our expectations will prove correct. All forward-looking statements included in this press release are expressly qualified in their entirety by the foregoing cautionary statements. You are cautioned not to place undue reliance on these forward-looking statements, which speak only as of today's date. We do not undertake any obligation to update, amend or clarify these statements or the “Risk Factors” contained in our most recent reports filed with the SEC, whether as a result of new information, future events or otherwise, except as may be required under the applicable securities laws.
Irene Paigah, 858-859-7001
Information om Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco
Følg pressemeddelelser fra Business Wire
Skriv dig op her og modtag pressemeddelelser på mail. Indtast din mail, klik på abonner og følg instruktionerne i den udsendte mail.
Flere pressemeddelelser fra Business Wire
CA-SKECHERS-USA-INC23.4.2018 09:02 | pressemeddelelse
Limited Edition Skechers D’Lites & Toei Animation One Piece Collection to Launch in Europe
SOFINNOVA-PARTNERS23.4.2018 08:02 | pressemeddelelse
Armance Bordes Joins Sofinnova Partners as General Counsel
REED-SINOPHARM23.4.2018 08:02 | pressemeddelelse
China’s Bakery Industry @ Bakery China 2018 (May 9-12, Shanghai)
ENAPTER23.4.2018 08:02 | pressemeddelelse
Enapter Showcases its Anion Exchange Membrane (AEM) Electrolyser at HANNOVER MESSE 2018.
GEMALTO23.4.2018 07:02 | pressemeddelelse
Gemalto Awarded Multi-Year Service Contract for New British Passports
ABB22.4.2018 12:02 | pressemeddelelse
ABB Showcases World-Leading e-Vehicle Fast Chargers and Launches AI Readiness Index at Hannover
I vores nyhedsrum kan du læse alle vores pressemeddelelser, tilgå materiale i form af billeder og dokumenter, og finde vores kontaktoplysninger.Besøg vores nyhedsrum